foscarnet has been researched along with dolutegravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bord, S; Borsa-Lebas, F; Caron, F; Chapuzet, C; Etienne, M; Leporrier, J; Mourez, T; Peytavin, G; Plantier, JC | 1 |
| Auge-Courtoi, C; Charpentier, C; Delory, T; Descamps, D; Matheron, S; Michard, F; Papot, E; Peytavin, G; Rioux, C; Yazdanpanah, Y | 1 |
2 other study(ies) available for foscarnet and dolutegravir
| Article | Year |
|---|---|
Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Foscarnet; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Salvage Therapy; Young Adult | 2014 |
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Foscarnet; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; HIV-2; Humans; Kidney; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load; Zidovudine | 2016 |